[go: up one dir, main page]

WO2016137164A3 - 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물 - Google Patents

바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물 Download PDF

Info

Publication number
WO2016137164A3
WO2016137164A3 PCT/KR2016/001665 KR2016001665W WO2016137164A3 WO 2016137164 A3 WO2016137164 A3 WO 2016137164A3 KR 2016001665 W KR2016001665 W KR 2016001665W WO 2016137164 A3 WO2016137164 A3 WO 2016137164A3
Authority
WO
WIPO (PCT)
Prior art keywords
bacillus
bacteria
extracellular vesicles
vesicles derived
composition including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/001665
Other languages
English (en)
French (fr)
Other versions
WO2016137164A2 (ko
Inventor
김윤근
김영주
지영구
노미나
문병인
김민혜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry University Cooperation Foundation IUCF HYU
Ewha Womans University
Industry Academic Cooperation Foundation of Dankook University
Original Assignee
Industry University Cooperation Foundation IUCF HYU
Ewha Womans University
Industry Academic Cooperation Foundation of Dankook University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry University Cooperation Foundation IUCF HYU, Ewha Womans University, Industry Academic Cooperation Foundation of Dankook University filed Critical Industry University Cooperation Foundation IUCF HYU
Priority to CN201680011779.4A priority Critical patent/CN107635571B/zh
Priority to US15/552,896 priority patent/US10550442B2/en
Priority to JP2017544611A priority patent/JP6475853B2/ja
Priority to EP16755814.7A priority patent/EP3263119B1/en
Publication of WO2016137164A2 publication Critical patent/WO2016137164A2/ko
Publication of WO2016137164A3 publication Critical patent/WO2016137164A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)

Abstract

본 발명은 임신관련 질환의 치료용 조성물에 관한 것으로서, 보다 구체적으로는 바실러스 속 세균에서 유래한 세포밖 소포체를 유효성분으로 포함하는 조산 또는 유방암의 예방 또는 치료용 약학적 조성물, 및 조산을 진단하기 위한 방법에 관한 것이다. 본 발명의 바실러스 속 세균 유래 세포밖 소포체를 유효성분으로 포함하는 약학적 조성물은 임신을 유도하거나 임산부의 조산을 예방할 수 있고, 유방암과 같은 임신관련 질환을 예방 또는 치료하는데 이용할 수 있으며, 임산부에서 바실러스 속 세균 유래 세포밖 소포체의 양을 측정함으로써 조산의 위험성을 진단하는데 유용하게 이용할 수 있다.
PCT/KR2016/001665 2015-02-23 2016-02-19 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물 Ceased WO2016137164A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201680011779.4A CN107635571B (zh) 2015-02-23 2016-02-19 含来源于芽孢杆菌属的细菌的细胞外囊泡的治疗妊娠相关疾病的组合物
US15/552,896 US10550442B2 (en) 2015-02-23 2016-02-19 Method for diagnosing premature delivery in a pregnant woman
JP2017544611A JP6475853B2 (ja) 2015-02-23 2016-02-19 バシラス属細菌由来の細胞外ベシクルを含む妊娠関連疾患の治療用の組成物
EP16755814.7A EP3263119B1 (en) 2015-02-23 2016-02-19 Method of determining risk of premature delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150025381A KR101726488B1 (ko) 2015-02-23 2015-02-23 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
KR10-2015-0025381 2015-02-23

Publications (2)

Publication Number Publication Date
WO2016137164A2 WO2016137164A2 (ko) 2016-09-01
WO2016137164A3 true WO2016137164A3 (ko) 2016-10-20

Family

ID=56789493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/001665 Ceased WO2016137164A2 (ko) 2015-02-23 2016-02-19 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물

Country Status (6)

Country Link
US (1) US10550442B2 (ko)
EP (1) EP3263119B1 (ko)
JP (1) JP6475853B2 (ko)
KR (1) KR101726488B1 (ko)
CN (1) CN107635571B (ko)
WO (1) WO2016137164A2 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160110232A (ko) * 2015-03-11 2016-09-21 주식회사 엠디헬스케어 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물
KR101833348B1 (ko) * 2016-12-26 2018-03-02 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 유방암 진단방법
KR101940426B1 (ko) * 2016-12-28 2019-01-18 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
WO2019004668A1 (ko) 2017-06-30 2019-01-03 주식회사 엠디헬스케어 프로테우스 속 세균 유래 나노소포 및 이의 용도
KR102011375B1 (ko) * 2017-06-30 2019-08-16 주식회사 엠디헬스케어 프로테우스 속 세균 유래 나노소포 및 이의 용도
AR113011A1 (es) 2017-09-08 2020-01-15 Evelo Biosciences Inc Vesículas extracelulares bacterianas
KR102095355B1 (ko) * 2018-01-12 2020-03-31 주식회사 엠디헬스케어 모르가넬라 속 세균 유래 나노소포 및 이의 용도
KR102087105B1 (ko) * 2018-02-21 2020-03-10 주식회사 엠디헬스케어 큐프리아비더스 속 세균 유래 나노소포 및 이의 용도
WO2019178055A1 (en) * 2018-03-12 2019-09-19 Evelo Biosciences, Inc. Extracellular vesicles from burkholderia
WO2020163724A1 (en) * 2019-02-08 2020-08-13 Board Of Regents, The University Of Texas System Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes
KR102558281B1 (ko) * 2020-03-04 2023-07-25 주식회사 엠디헬스케어 락토바실러스 속 세균 유래 세포밖 소포를 유효성분으로 포함하는 줄기세포 기능 조절용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090123875A (ko) * 2007-02-06 2009-12-02 콜롬비아 래버러토리즈 (버뮤다) 리미티드 조산 예방을 위한 프로제스테론
KR20110025603A (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 세균유래 세포밖 소포체 및 이의 용도
KR20110082481A (ko) * 2010-01-11 2011-07-19 포항공과대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
KR20120084900A (ko) * 2011-01-21 2012-07-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
US20140141102A1 (en) * 2010-10-27 2014-05-22 Dignity Health Trimegestone (tmg) for treatment of preterm birth

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05336896A (ja) * 1992-04-06 1993-12-21 Ajinomoto Co Inc 母豚用飼料組成物
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
WO2011027971A2 (ko) * 2009-09-01 2011-03-10 주식회사이언메딕스 장내 공생 세균유래 세포밖 소포체, 및 이를 이용한 질병모델, 백신, 후보 약물 탐색 방법, 및 진단 방법
US9086412B2 (en) * 2012-12-31 2015-07-21 University Of Louisville Research Foundation, Inc. Extracellular vesicle-associated protein markers of cancer
WO2014108480A1 (en) * 2013-01-09 2014-07-17 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles
CN103954770B (zh) * 2014-04-25 2015-09-30 江南大学 EVs-TRPC5在检测乳腺癌耐药程度中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090123875A (ko) * 2007-02-06 2009-12-02 콜롬비아 래버러토리즈 (버뮤다) 리미티드 조산 예방을 위한 프로제스테론
KR20110025603A (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 세균유래 세포밖 소포체 및 이의 용도
KR20110082481A (ko) * 2010-01-11 2011-07-19 포항공과대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
US20140141102A1 (en) * 2010-10-27 2014-05-22 Dignity Health Trimegestone (tmg) for treatment of preterm birth
KR20120084900A (ko) * 2011-01-21 2012-07-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOO, JAE YOUNG ET AL.: "16S rRNA Gene -based Metagenomic Analysis reveals Differences in Bacteria-derived Extracellular Vesicles in the Urine of Pregnant and Non-pregnant Women", EXP. MOL MED., vol. 48, 5 February 2016 (2016-02-05), pages e208, XP055321074 *

Also Published As

Publication number Publication date
KR101726488B1 (ko) 2017-04-13
CN107635571A (zh) 2018-01-26
WO2016137164A2 (ko) 2016-09-01
US10550442B2 (en) 2020-02-04
EP3263119A4 (en) 2018-08-15
CN107635571B (zh) 2021-09-28
EP3263119A2 (en) 2018-01-03
US20180057896A1 (en) 2018-03-01
KR20160102820A (ko) 2016-08-31
JP2018508510A (ja) 2018-03-29
JP6475853B2 (ja) 2019-02-27
EP3263119B1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
WO2016137164A3 (ko) 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
PH12018502634A1 (en) Topical compositions of apremilast
WO2019032662A8 (en) Clec9a binding agents and use thereof
WO2017066121A9 (en) Controlled and precise treatment of cardiac tissues
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
ZA201705874B (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
PH12019550265B1 (en) Composition comprising mannose oligosaccharide and process for making same and use thereof
EP4137147A3 (en) Uses of abaloparatide in reducing fracture risk
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
CR20210161A (es) Composiciones farmacéuticas semisólidas de base oleosa conteniendo pirfenidona para su aplicación en la reparación tisular
MX2015012526A (es) Inhibodores macrociclicos de cinasa rip2.
PH12019550300A1 (en) Human milk fortifier
EP4523542A3 (en) Human milk products useful in pre- and post-operative care
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
WO2018069831A3 (en) Ligands of the fsh hormone receptor in the diagnosis and treatment of tumors
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MY186523A (en) Macrocyclic rip2 kinase inhibitors
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MY188694A (en) Anticariogenic agent and anticariogenic composition
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2017544611

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15552896

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2016755814

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16755814

Country of ref document: EP

Kind code of ref document: A2